Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of nipocalimab in adults with moderate to severe Sjögren's disease
CTR20251667Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nipocalimab in Sjögren's syndrome, sponsored by Janssen Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20251667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251667.